Mines D'Or Orbec Announces First Batch of Assay Results from Summer 2025 Drill Campaign at Lac Bernard Sud Shows Promising Gold-Bearing Mineralization with Geologic Similarities to Adjacent Large Nelligan DiscoverySeptember 11, 2025 1:40 PM EDT | Source: Mines D'Or Orbec Inc.Brossard, Québec--(Newsfile Corp. - September 11, 2025) - Mines D'Or Orbec Inc. (TSXV: BLUE) (the "Company") is pleased to announce preliminary results from the inaugural seven-hole drill program (four holes being reported ...

Company Overview - Mines D'Or Orbec Inc. has entered into a debt settlement agreement to resolve outstanding severance payments totaling $76,325 by issuing 150,000 common shares at a deemed price of $0.509 per share [1] - The Board of Directors believes that settling the debt through share issuance is in the best interest of the Company to preserve cash for ongoing operations [1] Project Details - Orbec owns 100% of a significant mineral claim position near Chibougamau, Québec, covering approximately 25,250 hectares in the northeastern part of the Abitibi Greenstone Belt [3] - The Muus Project is prospective for gold mineralization and is adjacent to IAMGOLD's 8.3 million oz Nelligan Gold Project [3] - Exploration of the Muus Gold Project will advance in technical collaboration with IAMGOLD, which holds approximately 8.3% of Orbec [3] - Fieldwork completed in 2022 confirmed the northern portion of the Muus Gold Project is also prospective for copper-gold volcanogenic massive sulfide mineralization and high-grade gold similar to IAMGOLD's nearby Nelligan deposit [3]

Brossard, Quebec--(Newsfile Corp. - August 11, 2025) - Mines D'Or Orbec Inc. (TSXV: BLUE) (OTC Pink: BLTMF) ("Orbec" or the "Company") is pleased to announce the appointment of Mr. Jean-David Moore to an advisory role within the Company. With over 20 years of experience advising and consulting for numerous mineral exploration and development companies, Mr. Moore is a significant investor in the sector, holding equity positions in more than 50 junior mining companies across Québec and Canada, including over ...

Brossard, Quebec--(Newsfile Corp. - July 14, 2025) - Mines d'Or Orbec Inc. (TSXV: BLUE) (OTC Pink: BLTMF) is pleased to announce the successful completion of its 2,000+ metre spring 2025 drilling campaign at its 100% owned Muus property, located in Quebec's Abitibi Greenstone Belt. All assays are pending and are expected to be received from the independent laboratory in approximately 6 weeks. Nevertheless, based on the geology intersected by drilling in this campaign, the latest results further appear to co ...

Core Viewpoint - Brookdale Senior Living Inc. is urging shareholders to vote for its nominated directors, emphasizing that the current board's strategy is effectively driving shareholder value and operational momentum [1][3][11]. Financial Performance - In June, Brookdale achieved an 81.1% same community weighted average occupancy, with a month-end occupancy of 82.8%, indicating strong demand and sales execution [2]. - The second quarter weighted average consolidated occupancy was 80.1%, marking a significant milestone for cash flow growth [2]. - Since 2022, Brookdale has renegotiated leases for approximately 250 communities and reduced the number of leased units by 19% since Q1 2021, with plans to decrease its community portfolio to less than 600 by year-end 2025 from over 1,000 in 2017 [7]. Board Composition and Strategy - Brookdale's board consists of eight highly qualified directors, seven of whom are independent, with an average tenure of less than four years, ensuring a mix of skills critical for the company's growth [5][4]. - The board is actively engaged in a CEO search process, supported by an independent search firm, to find a candidate with the necessary experience in senior living, healthcare, hospitality, and real estate [6]. Shareholder Engagement - The company has made efforts to engage with Ortelius Advisors to avoid a proxy contest, but Ortelius has not engaged constructively [10]. - Brookdale emphasizes the importance of every shareholder vote and urges them to disregard any opposing proxy cards from Ortelius [12][11]. Competitive Positioning - Brookdale's operational improvements and strategic initiatives have positioned it to outperform peers in key metrics such as consolidated RevPAR, operating income per available unit, and adjusted EBITDA margin compared to 2019 [7]. - The company highlights that Ortelius lacks understanding of its business model and has proposed a flawed plan that could jeopardize Brookdale's progress [3][8].

Company Overview - Mines D'Or Orbec Inc. has completed a non-brokered private placement, raising a total of $1,005,000 through the issuance of 19,500,000 units and additional common shares [1][3] - The company owns 100% of a mineral claim position near Chibougamau, Québec, covering approximately 25,250 hectares in the Abitibi Greenstone Belt, which is prospective for gold and copper-gold mineralization [6] Offering Details - The second tranche of the offering consisted of 8,600,000 units sold at $0.05 per unit, generating gross proceeds of $430,000 [1][2] - Each unit includes one common share and one-half of a share purchase warrant, with warrants exercisable at $0.075 for 18 months [2] - The net proceeds will be allocated for exploration of the company's properties and general corporate purposes [3] Related Party Transactions - The Chairman and CEO of the company each purchased $35,000 worth of units in the offering, classified as a related party transaction [5] Regulatory and Financial Aspects - The shares and warrants are subject to a four-month hold period and require final approval from the TSX Venture Exchange [4] - Eligible finders received a 6% cash fee on the gross proceeds and finder warrants equivalent to 6% of the total units sold [4]

Core Viewpoint - Bluebird Bio reported a quarterly loss of $2.66 per share, which was better than the Zacks Consensus Estimate of a loss of $3.60, and significantly improved from a loss of $7.20 per share a year ago, indicating a positive earnings surprise of 26.11% [1] Financial Performance - The company posted revenues of $38.71 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 17.98%, but showing an increase from $18.57 million in the same quarter last year [2] - Over the last four quarters, Bluebird has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Bluebird shares have declined approximately 60.3% since the beginning of the year, contrasting with the S&P 500's gain of 0.1% [3] - The current Zacks Rank for Bluebird is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.20 on revenues of $68.8 million, and for the current fiscal year, it is -$15.19 on revenues of $282.8 million [7] - The trend of estimate revisions for Bluebird is mixed, which could change following the recent earnings report [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Bluebird belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Financial Performance - The company reported a net loss of $29.1 million for the three months ended March 31, 2025, with an accumulated deficit of $4.5 billion[148]. - Total revenue for the three months ended March 31, 2025, was $38.7 million, an increase of $20.1 million compared to $18.6 million for the same period in 2024, primarily due to eight additional infusions[177]. - The net loss for the three months ended March 31, 2025, was $29.1 million, a decrease of $40.7 million compared to a net loss of $69.8 million in the same period of 2024[177]. - Net cash used in operating activities for the three months ended March 31, 2025, was $43.4 million, a decrease from $74.7 million in the same period of 2024[189]. Cash and Liquidity - Cash and cash equivalents were approximately $78.7 million as of March 31, 2025, with restricted cash of $13.6 million[150][154]. - As of March 31, 2025, the company had cash and cash equivalents of approximately $78.7 million, primarily held in U.S. government agency securities and money market accounts[182]. - The company expects existing cash and cash equivalents to fund operations into June 2025, contingent on the completion of the Merger Transaction[185]. - The company cautions that its cash runway estimate may be affected by revenues and operating costs that could differ materially from current assumptions[154]. Research and Development - The company plans to continue incurring research and development expenses while scaling manufacturing capabilities for its gene therapies[152][165]. - Research and development expenses were $17.7 million for the three months ended March 31, 2025, down from $25.1 million in 2024, reflecting a decrease of $7.4 million[180]. - The accumulated deficit as of March 31, 2025, was $4.5 billion, with expectations for research and development expenses to decrease as commercial activities increase[183]. Mergers and Acquisitions - A merger agreement was announced on February 21, 2025, with a cash tender offer of $3.00 per share plus a contingent value right or $5.00 per share[149][157]. - The merger transaction is expected to close in the first half of 2025, which is critical for the company's liquidity[149][151]. - The company entered into a Merger Agreement on February 21, 2025, with expectations for completion in the first half of 2025[184]. Sales and Financing Activities - The company sold its first Rare Pediatric Disease Priority Review Voucher for net proceeds of $102.0 million and the second for $92.9 million in early 2023[145]. - In Q1 2023, the company sold its second PRV for aggregate net proceeds of $92.9 million[193]. - In Q1 2023, the company sold 1.2 million shares of common stock at $120.00 per share, generating aggregate net proceeds of $130.5 million[193]. - In December 2023, the company sold 4.2 million shares of common stock at $30.00 per share, resulting in aggregate net proceeds of $118.1 million[193]. - The company entered into a Loan Agreement for up to $175.0 million in debt financing in March 2024[193]. - The company has not made any sales pursuant to the Open Market Sales Agreement with Jefferies LLC as of March 31, 2025, which allows for sales up to $125.0 million[193]. Cost Management - Cost of product revenue decreased to $12.2 million for the three months ended March 31, 2025, from $25.9 million in the same period of 2024, attributed to reduced costs related to excess manufacturing capacity[178]. - Selling, general and administrative expenses decreased to $30.3 million for the three months ended March 31, 2025, from $46.3 million in 2024, a reduction of $16.1 million[179]. - The company has never been profitable and expects to continue incurring significant expenses and operating losses for the foreseeable future[148]. Regulatory Approvals - The FDA approved three gene therapies: ZYNTEGLO, SKYSONA, and LYFGENIA, with commercialization efforts focused in the U.S.[140][141]. Market Risks - The company has exposure to market risk related to changes in interest rates, primarily due to investments in short-term securities[194].

Chibougamau, Quebec--(Newsfile Corp. - May 9, 2025) - Mines D'Or Orbec/Orbec Gold Mines (TSXV: BLUE) (OTC Pink: BLTMF) is pleased to announce the company is participating in the upcoming 121 Mining Investment Conference in London. John Tait, CEO of Mines D'Or Orbec/Orbec Gold Mines will be presenting about the Company's recent and future planned activities. 121 Mining Investment London will be hosting over 110 mining companies and more than 650 sophisticated investors for two days of pre-arranged, targete ...

Core Viewpoint - Ayrmid Ltd. has made an unsolicited proposal to acquire Bluebird Bio, offering $4.50 per share in cash and a contingent value right of $6.84 per share based on net sales milestones [1] Group 1: Acquisition Proposals - Ayrmid's proposal includes an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share [1] - In February 2025, Bluebird entered into a definitive agreement with Carlyle and SK Capital Partners for an acquisition at $3.00 per share in cash, also with a contingent value right of $6.84 per share [2] - Bluebird previously engaged in discussions with Ayrmid during a strategic review but did not receive a proposal at that time [3] Group 2: Regulatory Concerns - The FDA raised concerns in November 2024 regarding life-threatening hematologic malignancies associated with Bluebird's gene therapy Skysona, with reports of myelodysplastic syndrome and acute myeloid leukemia linked to the treatment [4] - Cases of these malignancies were reported to emerge 14 to 92 months post-treatment during clinical trials [4] Group 3: Market Reaction - Following the news, Bluebird's stock price increased by 7.84%, reaching $4.40 [4]